Not 100% sure. Im assuming it would not prevent management from buying.
1. Investigator lead trial
2. Not an end point
3. Info can be held back for IP purposes if commercially sensitive
4. Its more observational, investigation type work as opposed to Success/Failure
We all know FTO as a target could be extremely valuable if used appropriately, and is price sensitive to the market with the right context, background etc. but this data in isolation could prob be held back and not an issue for management.
Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett, page-142
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |